Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$239M+134.4% YoY

Gross Profit

$147M61.6% margin

Operating Income

$86M35.8% margin

Net Income

$61M25.6% margin

EPS (Diluted)

$0.86

QoQ Revenue Growth

+7.0%

Cash Flow

Operating Cash Flow

$94M

Free Cash Flow

$87M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$458M

Stockholders' Equity

$638M

Cash & Equivalents

$257M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$239M	$102M	+134.4%
Gross Profit	$147M	$43M	+245.5%
Operating Income	$86M	-$14M	+698.4%
Net Income	$61M	-$13M	+556.4%

Revenue Segments

Product

$233M33%

Radiopharmaceutical Oncology

$145M20%

PYLARIFY

$144M20%

Total Precision Diagnostics

$89M12%

DEFINITY

$61M9%

Techne Lite

$22M3%

Other Precision Diagnostics

$6M1%

License and Royalty Revenues

$6M1%

Strategic Partnerships And Other

$6M1%

Other Radiopharmaceutical Oncology

$928,0000%